scholarly journals Unusual mixed germ cell testicular carcinoma with pancreatic metastases in a young man

2021 ◽  
Vol 9 (39) ◽  
pp. 86-88
Author(s):  
Annia Cavazos ◽  
Cristina Morataya ◽  
Gaspar Del Rio-Pertuz ◽  
Kenneth Iwuji
2005 ◽  
Vol 47 (1) ◽  
pp. 48-56 ◽  
Author(s):  
C E Hoei-Hansen ◽  
K Almstrup ◽  
J E Nielsen ◽  
S Brask Sonne ◽  
N Graem ◽  
...  

2006 ◽  
Vol 449 (2) ◽  
pp. 200-206 ◽  
Author(s):  
Si Brask Sonne ◽  
Amy S. Herlihy ◽  
Christina E. Hoei-Hansen ◽  
John E. Nielsen ◽  
Kristian Almstrup ◽  
...  

Apmis ◽  
2003 ◽  
Vol 111 (1) ◽  
pp. 267-279 ◽  
Author(s):  
EWA RAJPERT-DE MEYTS ◽  
JIRINA BARTKOVA ◽  
MICHEL SAMSON ◽  
CHRISTINA E. HOEI-HANSEN ◽  
LONE FRYDELUND-LARSEN ◽  
...  

2004 ◽  
Vol 10 (24) ◽  
pp. 8521-8530 ◽  
Author(s):  
Christina E. Hoei-Hansen ◽  
John E. Nielsen ◽  
Kristian Almstrup ◽  
Si Brask Sonne ◽  
Niels Graem ◽  
...  

2002 ◽  
Vol 83 (9) ◽  
pp. 2321-2324 ◽  
Author(s):  
T. Tolfvenstam ◽  
N. Papadogiannakis ◽  
A. Andersen ◽  
O. Akre

The incidence of testicular germ cell cancer, which is the most common cancer among young male adults, is increasing. The aetiology remains unknown, although a virus has been proposed. A previous study has shown a high prevalence of human parvovirus B19 (B19) DNA in the testes of patients with testicular germ cell tumours (85%) and suggested that B19 may play a role in tumour development. To address this question of causality, seroreactivity to B19 was studied among cases (n=80) and controls (n=241) using serum samples drawn before the onset of disease, in addition to an elucidation of the frequency of virus DNA in a retrospectively collected 2-year testicular carcinoma series. No association was found between B19 seropositivity and the risk of testicular cancer (odds ratio=1·03; 95% confidence interval=0·60–1·77) nor was there any dose-response relation (P for trend=0·53). This study did, however, confirm the observation that B19 DNA can be detected in testicular carcinoma tissue, as 4 of 24 cases were found to be positive, while no B19 DNA could be detected in the control cases. It is speculated that this finding may be due to susceptibility of the carcinoma cells to B19 virus owing to high-level expression of the viral receptor glycosphingolipid (Gb4) and possible other putative cellular factors resulting in a localized persistence initiated after the development of cancer.


1983 ◽  
Vol 1 (3) ◽  
pp. 171-178 ◽  
Author(s):  
N J Vogelzang ◽  
E E Fraley ◽  
P H Lange ◽  
J Torkelson ◽  
S Levitt ◽  
...  

Between 1970 and 1980, 82 patients with pathologic stage II nonseminomatous germ cell testicular carcinoma were treated at the University of Minnesota. Of the 30 patients treated with a retroperitoneal lymph node dissection, 22 (77%) relapsed. Of the 18 patients treated with retroperitoneal lymph node dissection and adjuvant radiotherapy, 12 (63%) relapsed. Sixteen patients received adjuvant chemotherapy before 1976, and 14 (87.5%) relapsed. After 1976, 18 patients received adjuvant chemotherapy (11 with cisplatin) and 2 (11%) have relapsed. No patient treated with cisplatin-based adjuvant chemotherapy has relapsed. The toxicity has been modest. Cisplatin-based chemotherapy is an effective and a safe adjuvant therapy for stage II nonseminomatous germ cell testicular carcinoma.


2003 ◽  
Vol 14 (9) ◽  
pp. 1412-1418 ◽  
Author(s):  
S.D. Fosså ◽  
N. Aass ◽  
A. Heilo ◽  
G. Daugaard ◽  
N.E. Skakkebæk ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document